There is a stepwise efficacy decline for acute stroke treatments from experimental studies to early clinical trials to Phase III clinical trials, which is explained by publication bias, noncompliance with quality criteria, significant differences in study design, and low power of experimental studies and early clinical trials.
Why this matters
A majority of acute stroke treatments that show promise in animal studies eventually fail in large clinical trials.
Further understanding this trend, and the factors contributing to it, will aid in the development of better clinical trials and, potentially, new treatments.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.